文献速递精神分裂症与精神病性障碍

抗精神病药使用降低首发非情感性精神病患者工作残疾风险:瑞典全国队列自身对照分析

Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.
PubMed 文献 · Am J Psychiatry · 2022-10-06

该研究基于瑞典全国21,551例首发非情感性精神病患者(16-45岁),采用自身对照设计比较抗精神病药使用与不使用期间的工作残疾风险。结果显示,用药期间工作残疾风险显著低于不使用期间(aHR=0.65,95%CI=0.59-0.72),长效针剂风险最低(aHR=0.46,95%CI=0.34-0.62),且该关联在诊断后5年以上仍持续。

要点

  • 抗精神病药使用与工作残疾风险降低约30%-50%相关(aHR=0.65)。
  • 长效针剂风险最低(aHR=0.46),优于最常用口服奥氮平(aHR=0.68)。
  • 风险降低在诊断后<2年、2-5年及>5年 periods 均相似。

核心结论

  • 首发非情感性精神病患者中,抗精神病药使用与工作残疾风险降低约30%-50%相关,长效针剂尤为明显,且该关联在首发诊断5年后仍成立。

研究设计与样本

  • 采用自身对照设计,基于瑞典全国首发非情感性精神病患者队列(N=21,551,年龄16-45岁),随访最长11年(2006-2016),使用分层Cox回归模型并调整时变因素,以个体自身为对照消除选择偏倚。

主要发现

  • 中位随访4.8年期间,45.9%的首发患者出现工作残疾。
  • 使用任何抗精神病药期间工作残疾风险低于不使用期间(aHR=0.65,95%CI=0.59-0.72)。
  • 长效针剂调整风险比最低(aHR=0.46,95%CI=0.34-0.62),口服阿立哌唑(aHR=0.68,95%CI=0.56-0.82)和口服奥氮平(aHR=0.68,95%CI=0.59-0.78)次之。
  • 长效针剂风险低于最常用口服奥氮平(aHR=0.68,95%CI=0.50-0.94)。
  • 诊断后<2年、2-5年及>5年期间调整风险比相似。

临床怎么用

  • 对首发非情感性精神病患者,应重视抗精神病药维持治疗对降低工作残疾风险的作用,长效针剂可能更具优势。

局限性

  • 研究结果需重复验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors sought to determine whether antipsychotic use, compared with nonuse, is associated with lower work disability in first-episode nonaffective psychosis, and if so, for how long. METHODS: A within-subject design was used to study the risk of sickness absence or disability pension during antipsychotic use compared with nonuse during a maximum of 11 years of follow-up (2006-2016) in a Swedish nationwide cohort of patients with first-episode nonaffective psychosis (N=21,551; age range, 16-45 years). The within-subject analyses were conducted with stratified Cox regression models, adjusted for time-varying factors, using each individual as her or his own control to eliminate selection bias. The primary outcome was work disability (sickness absence or disability pension). RESULTS: Overall, 45.9% of first-episode patients had work disability during the median length of follow-up of 4.8 years. The risk of work disability was lower during use compared with nonuse of any antipsychotic (adjusted hazard ratio [aHR]=0.65, 95% CI=0.59-0.72). The lowest adjusted hazard ratios emerged for long-acting injectable antipsychotics (aHR=0.46, 95% CI=0.34-0.62), oral aripiprazole (aHR=0.68, 95% CI=0.56-0.82), and oral olanzapine (aHR=0.68, 95% CI=0.59-0.78). Long-acting injectables were associated with lower risk than olanzapine, the most commonly used oral antipsychotic (aHR=0.68, 95% CI=0.50-0.94). Adjusted hazard ratios were similar during the periods of <2 years, 2-5 years, and >5 years since diagnosis. CONCLUSIONS: Among individuals with first-episode nonaffective psychosis, antipsychotic treatment (with long-acting injectables in particular) was associated with about 30%-50% lower risk of work disability compared with nonuse of antipsychotics in the same individuals, which held true beyond 5 years after first diagnosis. These findings are informative regarding the important topic of early discontinuation of antipsychotic treatment after a first episode of nonaffective psychosis, but they need replication.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Solmi M, Taipale H, Holm M, et al. Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis. Am J Psychiatry. 2022. PMID: 36200276. doi:10.1176/appi.ajp.21121189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。